Association of Polymorphisms in PPARPGC1A, ACE, and DRD2 Genes with Gestational Diabetes Mellitus

ORIGINAL ARTICLE
Agamurad A. Orazmuradov, Irina V. Bekbaeva, Gayane A. Arakelyan, Marianna Z. Abitova, Khalid Haddad, Alexander M. Lopatin, Sergey I. Kyrtikov, Gulnoza K. Eldashova, Ekaterina V. Mukovnikova, Aleksey A. Lukaev

 
International Journal of Biomedicine. 2021;11(1):42-45.
DOI: 10.21103/Article11(1)_OA8
Originally published March 5, 2021

Abstract: 

The aim of our research was to study the distribution of polymorphic variants of the DRD2/ANKK1 TaqIA (rs1800497 SNP), PPARGC1A rs8192678 SNP, and ACE I/D in gestational diabetes mellitus (GDM).
Methods and Results: The study included 383 pregnant women (gestational age of 37.0–41.0 weeks) with GDM and 68 pregnant women without disturbed carbohydrate metabolism. This was a prospective case-control study. All patients were divided into 3 groups. Group 1 included 211 pregnant women with GDM who received diet therapy only; Group 2 included 172 pregnant women with GDM who received insulin therapy; Group 3 included 68 pregnant women without metabolic disorders. For the DRD2/ANKK1 TaqIA (rs1800497 SNP) (A1/A2; T/C), we found that the TT homozygous genotype and T allele prevailed in Groups with GDM compared with Group without metabolic disorders.
Conclusion: A study of the DRD2/ANKK1 TaqIA (rs1800497 SNP), PPARGC1A rs8192678 SNP, and ACE I/D revealed statistically significant increased risks for GDM in carriers of the TT genotype and T allele of the DRD2/ANKK1 TaqIA (rs1800497 SNP).

Keywords: 
gestational diabetes mellitus • dopamine D2 receptor • PPARPGC-1A • angiotensin-converting enzyme
References: 
  1. Radzinsky VE, Botasheva TL, Kotaysh GA. Obesity. Diabetes. Pregnancy. Versions and contraversions, clinical practices, prospects.  M.: GEOTAR-Media, 2020.
  2.  Orazmuradov AA, Akhmatova AN, Savenkova IV, Arakelyan GA, Damirova KF, Haddad Kh., Orazmuradova AA. Influence of Gestational Weight Gain on the Development of Complications of Gestational Diabetes Mellitus: A Literature Review. Sys Rev Pharm. 2020;11(7):462-464.
  3. Orazmuradov AA, Savenkova IV, Arakelyan GA, Damirova SF, Papysheva OV, Lukanovskaya OB. Peculiar Properties of Metabolism Women with Gestational Diabetes Mellitus. Sys Rev Pharm. 2020;11(2):237-241.
  4. Orazmuradov AA, Damirova SF, Savenkova IV, Arakelyan GA, Barinova EK, Haddad Kh. Prediction and Pregravid Preparation of Women with High-Risk Development of Gestational Diabetes Mellitus. Sys Rev Pharm. 2020;11(6):175-178.
  5.  Orazmuradov AA, Papysheva OV, Soyunov MA, Bekbaeva IV, Arakelyan GA, Haddad Kh, Lopatin AM, et al.  Peculiar Properties of Pregnancy and Childbirth in Women with Gestational Diabetes Mellitus Depending on Body Weight. Sys Rev Pharm. 2020 11(11):1338-1340.
  6. Aggarwal P, Agarwal N, Das N, Dalal K. Association of polymorphisms in angiotensin-converting enzyme gene with gestational diabetes mellitus in Indian women. Int J Appl Basic Med Res. 2016 Jan-Mar;6(1):31-7. doi: 10.4103/2229-516X.174006. 
  7. Zhou JB, Yang JK, Lu JK, An YH. Angiotensin-converting enzyme gene polymorphism is associated with type 2 diabetes: a meta-analysis. Mol Biol Rep. 2010 Jan;37(1):67-73. doi: 10.1007/s11033-009-9648-6. 
  8. Mirfeizi M, Hasanzad M, Sattari M, Afshari M, Abbasi D, Ajoodani Z, Sheykheslam AB. Association of eNOS and ACE gene polymorphisms as a genetic risk factor in gestational diabetes in Iranian women. J Diabetes Metab Disord. 2018 Aug 6;17(2):123-127. doi: 10.1007/s40200-018-0348-4. Erratum in: J Diabetes Metab Disord. 2020 Jun 25;19(2):2063.
  9. Wu H, Deng X, Shi Y, Su Y, Wei J, Duan H. PGC-1α, glucose metabolism and type 2 diabetes mellitus. J Endocrinol. 2016 Jun;229(3):R99-R115. doi: 10.1530/JOE-16-0021.
  10. Vohl MC, Houde A, Lebel S, Hould FS, Marceau P. Effects of the peroxisome proliferator-activated receptor-gamma co-activator-1 Gly482Ser variant on features of the metabolic syndrome. Mol Genet Metab. 2005 Sep-Oct;86(1-2):300-6. doi: 10.1016/j.ymgme.2005.07.002. 
  11. Rodgers JT, Lerin C, Gerhart-Hines Z, Puigserver P. Metabolic adaptations through the PGC-1 alpha and SIRT1 pathways. FEBS Lett. 2008 Jan 9;582(1):46-53. doi: 10.1016/j.febslet.2007.11.034. 
  12. Choi YS, Hong JM, Lim S, Ko KS, Pak YK. Impaired coactivator activity of the Gly482 variant of peroxisome proliferator-activated receptor gamma coactivator-1alpha (PGC-1alpha) on mitochondrial transcription factor A (Tfam) promoter. Biochem Biophys Res Commun. 2006 Jun 9;344(3):708-12. doi: 10.1016/j.bbrc.2006.03.193. 
  13. Fanelli M, Filippi E, Sentinelli F, Romeo S, Fallarino M, Buzzetti R, Leonetti F, Baroni MG. The Gly482Ser missense mutation of the peroxisome proliferator-activated receptor gamma coactivator-1 alpha (PGC-1 alpha) gene associates with reduced insulin sensitivity in normal and glucose-intolerant obese subjects. Dis Markers. 2005;21(4):175-80. doi: 10.1155/2005/576748. 
  14. Savitz J, Hodgkinson CA, Martin-Soelch C, Shen PH, Szczepanik J, Nugent AC, Herscovitch P, Grace AA, Goldman D, Drevets WC. DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder. Int J Neuropsychopharmacol. 2013 Oct;16(9):2095-101. doi: 10.1017/S146114571300045X. 
  15. Noble EP, Noble RE, Ritchie T, Syndulko K, Bohlman MC, Noble LA, Zhang Y, Sparkes RS, Grandy DK. D2 dopamine receptor gene and obesity. Int J Eat Disord. 1994 Apr;15(3):205-17.
  16. Stice E, Yokum S, Zald D, Dagher A. Dopamine-based reward circuitry responsivity, genetics, and overeating. Curr Top Behav Neurosci. 2011;6:81-93. doi: 10.1007/7854_2010_89.
  17. Cardel MI, Lemas DJ, Lee AM, Miller DR, Huo T, Klimentidis YC, Fernandez JR. Taq1a polymorphism (rs1800497) is associated with obesity-related outcomes and dietary intake in a multi-ethnic sample of children. Pediatr Obes. 2019 Feb;14(2):e12470. doi: 10.1111/ijpo.12470. 
  18. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol. 2018 Feb;131(2):e49-e64. doi: 10.1097/AOG.0000000000002501.
  19. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature. 1992 Oct 15;359(6396):641-4. doi: 10.1038/359641a0. 
  20. Ek J, Andersen G, Urhammer SA, Gaede PH, Drivsholm T, Borch-Johnsen K, Hansen T, Pedersen O. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to Type II diabetes mellitus. Diabetologia. 2001 Dec;44(12):2220-6. doi: 10.1007/s001250100032. 
  21. Grandy DK, Zhang Y, Civelli O. PCR detection of the TaqA RFLP at the DRD2 locus. Hum Mol Genet. 1993 Dec;2(12):2197. doi: 10.1093/hmg/2.12.2197-a. 
  22. Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol. 2009 Feb 15;169(4):505-14. doi: 10.1093/aje/kwn359. 
  23. Andersen G, Hansen T, Gharani N, Fraiyling TM, Owen KR, Sampson M, Ellard S, Walker M, Hitman GA, Hattersley A, Mccarthy MI, Pedersen O. A common Gly482Ser polymorphism of PGC-1 is associated with type 2 diabetes mellitus in two European populations. Diabetes. 2002;51:A49–50. 
  24.  Kunej T, Globocnik Petrovic M, Dovc P, Peterlin B, Petrovic D. A Gly482Ser polymorphism of the peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) gene is associated with type 2 diabetes in Caucasians. Folia Biol (Praha). 2004;50(5):157-8.
  25. Shokouhi S, Haghani K, Borji P, Bakhtiyari S. Association between PGC-1alpha gene polymorphisms and type 2 diabetes risk: a case-control study of an Iranian population. Can J Diabetes. 2015 Feb;39(1):65-72. doi: 10.1016/j.jcjd.2014.05.003. 
  26. Jemaa Z, Kallel A, Sleimi C, Mahjoubi I, Feki M, Ftouhi B, Slimane H, Jemaa R, Kaabachi N. The Gly482Ser polymorphism of the peroxisome proliferator-activated receptor-g coactivator-1a (PGC-1a) is associated with type 2 diabetes in Tunisian population. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2015;9(4):316–319. 
  27. Villegas R, Williams SM, Gao YT, Long J, Shi J, Cai H, Li H, Chen CC, Tai ES; AGEN-T2D Consortium, Hu F, Cai Q, Zheng W, Shu XO. Genetic variation in the peroxisome proliferator-activated receptor (PPAR) and peroxisome proliferator-activated receptor gamma co-activator 1 (PGC1) gene families and type 2 diabetes. Ann Hum Genet. 2014 Jan;78(1):23-32. doi: 10.1111/ahg.12044.
  28.  Lacquemant C, Chikri M, Boutin P, Samson C, Froguel P. No association between the G482S polymorphism of the proliferator-activated receptor-gamma coactivator-1 (PGC-1) gene and Type II diabetes in French Caucasians. Diabetologia. 2002 Apr;45(4):602-3; author reply 604. doi: 10.1007/s00125-002-0783-z.
  29.  Stumvoll M, Fritsche A, t'Hart LM, Machann J, Thamer C, Tschritter O, Van Haeften TW, Jacob S, Dekker JM, Maassen JA, Machicao F, Schick F, Heine RJ, Häring H. The Gly482Ser variant in the peroxisome proliferator-activated receptor gamma coactivator-1 is not associated with diabetes-related traits in non-diabetic German and Dutch populations. Exp Clin Endocrinol Diabetes. 2004 May;112(5):253-7. doi: 10.1055/s-2004-817972. 
  30. Vohl MC, Houde A, Lebel S, Hould FS, Marceau P. Effects of the peroxisome proliferator-activated receptor-gamma co-activator-1 Gly482Ser variant on features of the metabolic syndrome. Mol Genet Metab. 2005 Sep-Oct;86(1-2):300-6. doi: 10.1016/j.ymgme.2005.07.002. 
  31.  Esterbauer H, Oberkofler H, Linnemayr V, Iglseder B, Hedegger M, Wolfsgruber P, Paulweber B, Fastner G, Krempler F, Patsch W. Peroxisome proliferator-activated receptor-gamma coactivator-1 gene locus: associations with obesity indices in middle-aged women. Diabetes. 2002 Apr;51(4):1281-6. doi: 10.2337/diabetes.51.4.1281. 
  32. McGuire V, Van Den Eeden SK, Tanner CM, Kamel F, Umbach DM, Marder K, Mayeux R, Ritz B, Ross GW, Petrovitch H, Topol B, Popat RA, Costello S, Manthripragada AD, Southwick A, Myers RM, Nelson LM. Association of DRD2 and DRD3 polymorphisms with Parkinson's disease in a multiethnic consortium. J Neurol Sci. 2011 Aug 15;307(1-2):22-9. doi: 10.1016/j.jns.2011.05.031. 
  33. Barnard ND, Noble EP, Ritchie T, Cohen J, Jenkins DJ, Turner-McGrievy G, Gloede L, Green AA, Ferdowsian H. D2 dopamine receptor Taq1A polymorphism, body weight, and dietary intake in type 2 diabetes. Nutrition. 2009 Jan;25(1):58-65. doi: 10.1016/j.nut.2008.07.012.
  34. Ramos-Lopez O, Mejia-Godoy R, Frías-Delgadillo KJ, Torres-Valadez R, Flores-García A, Sánchez-Enríquez S, Aguiar-García P, Martínez-López E, Zepeda-Carrillo EA. Interactions between DRD2/ANKK1 TaqIA Polymorphism and Dietary Factors Influence Plasma Triglyceride Concentrations in Diabetic Patients from Western Mexico: A Cross-sectional Study. Nutrients. 2019 Nov 22;11(12):2863. doi: 10.3390/nu11122863.
  35. Papysheva OV, Nurbekov MK, Mayatskaya TA, Kotaysh GA, Kozhevnikova EN, Shchipkova ES, Morozov SG. Influence of the PGC1α, АСЕ and DRD2 gene polymorphisms on the development and the course of gestational diabetes. Gynecology, Obstetrics and Perinatology. 2020;19(3):63–71. doi: 10.20953/1726-1678-2020-3-63-71. [Article in Russian].

Download Article
Received February 18, 2021.
Accepted March 3, 2021.
©2021 International Medical Research and Development Corporation.